Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
| Line 15: | Line 15: | ||
*'''Generic name:''' caplacizumab-yhdp | *'''Generic name:''' caplacizumab-yhdp | ||
*'''Brand name:''' Cablivi | *'''Brand name:''' Cablivi | ||
| + | |||
| + | ==References== | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 10:22, 4 April 2021
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Diseases for which it is used
History of changes in FDA indication
- 2/6/2019: Initial approval for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Patient Drug Information
Also known as
- Code name: ALX-0081
- Generic name: caplacizumab-yhdp
- Brand name: Cablivi